首页> 美国卫生研究院文献>Nutrients >Eckol from Ecklonia cava Suppresses Immunoglobulin E-mediated Mast Cell Activation and Passive Cutaneous Anaphylaxis in Mice (Running Title: Anti-Allergic Activity of Ecklonia cava)
【2h】

Eckol from Ecklonia cava Suppresses Immunoglobulin E-mediated Mast Cell Activation and Passive Cutaneous Anaphylaxis in Mice (Running Title: Anti-Allergic Activity of Ecklonia cava)

机译:来自Ecklonia cava的Eckol抑制小鼠免疫球蛋白E介导的肥大细胞活化和被动皮肤过敏反应(正在运行的标题:Ecklonia cava的抗过敏活性)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Eckol, a precursor compound belonging to the dibenzo-1,4-dioxin class of phlorotannins, is a phloroglucinol derivative that exerts various activities. In the present study, we investigated the antiallergic effects of eckol isolated from the marine brown algae, using immunoglobulin E (IgE)/bovine serum albumin (BSA)-stimulated mouse bone marrow-derived cultured mast cells (BMCMC) and a mouse model of anaphylaxis. Eckol inhibited IgE/BSA-induced BMCMC degranulation by reducing β-hexosaminidase release. A flow cytometric analysis revealed that eckol decreases FcεRI expression on cell surface and IgE binding to the FcεRI in BMCMC. Moreover, eckol suppressed the production of the cytokines, interleukin (IL)-4, IL-5, IL-6, and IL-13 and the chemokine, thymus activation-regulated chemokine (TARC) by downregulating, IκB-α degradation and NF-κB nuclear translocation. Furthermore, it attenuated the passive cutaneous anaphylactic reaction induced by IgE/BSA-stimulation in the ear of BALB/c mice. These results suggest that eckol is a potential therapeutic candidate for the prevention and treatment of allergic disorders.
机译:Eckol是属于邻苯二酚二苯并-1,4-二恶英类的前体化合物,是一种具有多种活性的间苯三酚衍生物。在本研究中,我们使用免疫球蛋白E(IgE)/牛血清白蛋白(BSA)刺激的小鼠骨髓源性培养的肥大细胞(BMCMC)和小鼠模型,研究了从海洋褐藻中分离的eckol的抗过敏作用。过敏反应。 Eckol通过减少β-己糖胺酶的释放来抑制IgE / BSA诱导的BMCMC脱粒。流式细胞仪分析显示,eckol降低了BMCMC中细胞表面FcεRI的表达以及IgE与FcεRI的结合。此外,eckol通过下调IκB-α降解和NF抑制细胞因子,白介素(IL)-4,IL-5,IL-6和IL-13和趋化因子,胸腺激活调节趋化因子(TARC)的产生。 -κB核易位。此外,它减弱了BALB / c小鼠耳中IgE / BSA刺激引起的被动皮肤过敏反应。这些结果表明,eckol是预防和治疗过敏性疾病的潜在治疗候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号